Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)

Next Previous
Trial Profile

Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vinflunine (Primary) ; Carboplatin; Cisplatin; Cyclophosphamide; Melphalan; Mitomycin; Thiotepa
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pierre Fabre

Most Recent Events

  • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jun 2015 Status changed from active, no longer recruiting to completed as result presented at 51st Annual Meeting of the American Society of Clinical Oncology.
  • 19 Aug 2013 Planned end date changed from 1 Aug 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top